Search

2024 SEP 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on mycosis fungoides are presented in a new report. According [...]

Innate Pharma SA reported favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides (MF). The company said the results were presented at the recent ASCO 2024 [...]

A recent study conducted at the Mayo Clinic in Rochester, Minnesota has found that machine learning can accurately identify Sezary cells, which are important for diagnosing and staging certain skin conditions. The researchers used a simplified analysis method that only required two predefined cell-gating plots. The results of the study showed that the machine learning approach closely matched the results obtained through expert analysis. This research demonstrates the potential of machine learning to simplify the identification of Sezary cells. [Extracted from the article]

A recent study conducted by Castle Biosciences Inc. examined the contemporary treatment patterns for atopic dermatitis (AD). The study analyzed real-world data from US medical and prescription claims and found that over 50% of patients discontinued or switched therapies, indicating inadequate disease control. The study also revealed that patients who persisted on dupilumab treatment despite continuing pruritus had higher rates of post-index biopsy and other cutaneous diagnoses, suggesting an unclear diagnosis or multiple pruritic conditions. The findings highlight the need for more proactive management strategies in the context of emerging treatment options for AD. [Extracted from the article]

A 53-year-old woman with stage IVA1 mycosis fungoides experienced lack of efficacy during treatment with romidepsin and developed oral mucosal hyperpigmentation during treatment with doxorubicin-liposomal. She had a history of the disease and received 5 cycles of romidepsin, which did not effectively treat her condition. However, after receiving 4 doses of doxorubicin-liposomal, she showed a good response. She later developed hyperpigmentation of the oral mucosa, but it resolved after completing the course of doxorubicin-liposomal treatment. [Extracted from the article]

A 73-year-old man developed erythroderma, a skin condition, while being treated with brentuximab vedotin for mycosis fungoides (MF). The man initially presented with facial erythema and later developed nodules on top of it. After receiving several courses of brentuximab vedotin, he developed erythema on his hands, which spread to his entire body. Laboratory findings showed increased levels of lactate dehydrogenase and eosinophils. The man was diagnosed with erythroderma secondary to brentuximab vedotin and his treatment was stopped. He received betamethasone butyrate propionate and his symptoms improved, but MF recurred three months later. [Extracted from the article]

A recent report from Tishreen University provides a comprehensive review of mycosis fungoides (MF), the most common type of primary cutaneous T-cell lymphoma. MF is known for its wide range of clinical manifestations that can mimic various skin disorders, making diagnosis challenging. The study focuses on the different clinical and histopathological variants of MF and their differential diagnoses. The research emphasizes the importance of recognizing these variants to improve prognosis and timely treatment. For more information, readers can contact Jacob Al-Dabbagh at Tishreen University. [Extracted from the article]

A recent report from researchers at Centro Hospitalar Universitario de Lisboa Central in Lisbon, Portugal, discusses the trichoscopic findings in folliculotropic mycosis fungoides (FMF), a type of cutaneous lymphoma. The report focuses on a case study of a 50-year-old man with FMF stage IB, describing the clinical findings and trichoscopic evaluation of his condition. The researchers suggest that trichoscopic evaluation could be useful in guiding differential diagnosis and identifying early disease. This information may be valuable for individuals conducting research on mycosis fungoides and related dermatological conditions. [Extracted from the article]

The article offers information on an atypical case of mycosis fungoides with a rare phenotype and SOCS1 mutation. Topics discussed include the diagnostic challenges due to similarities with benign skin disorders; the unique blastic morphology and cytotoxic phenotype of the T-cell lymphoma; and the identification of a likely pathogenic SOCS1 mutation and STAT3 variant through next-generation sequencing.

A case report in the journal Reactions Weekly describes the experience of a woman in her early 60s who developed mild oral mucositis while being treated with methotrexate for mycosis fungoides. She also experienced lack of efficacy when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone for the same condition. The woman's symptoms worsened and new lesions appeared, leading to the need for urgent treatment. After trying different therapies, including radiotherapy and various medications, the woman eventually achieved close to complete remission of her symptoms after a follow-up period of 2 years and 5 months. [Extracted from the article]

A recent article from Hematology Week discusses the pathophysiology of Cutaneous T-Cell Lymphoma (CTCL) and the advancements made in understanding this diverse group of malignant blood disorders. The most common form of CTCL is Mycosis fungoides, characterized by initial skin infiltration and potential spreading to other areas. Another distinct form of CTCL is Sezary syndrome, which involves a significant presence of circulating tumor cells in the blood. The article highlights the plasticity and heterogeneity of tumor cells in different tissue compartments, as well as the challenges in diagnosing and monitoring these diseases. The research, conducted at Saint-Louis Hospital in Paris, provides a review of recent advancements in the field. [Extracted from the article]

Researchers at Thomas Jefferson University in Philadelphia have reported on a case of coexistence between large cell transformed mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL) in one patient. The patient, an 81-year-old female, presented with a tumor on her leg and lymphadenopathy in her right axilla. Skin biopsy revealed large atypical CD3+, CD4+, and CD30+ cells consistent with LCT MF, while biopsy of the lymph node revealed diffuse sheets of CD20+, BCL-2+, c-MYC+, and CD10- cells suggestive of double expressor DLBCL. The case highlights the importance of a full pathological workup in cutaneous T-cell lymphoma patients with lymphadenopathy. [Extracted from the article]

A study conducted by researchers at New York University (NYU) examined front-line treatments and quality of life in patients with newly diagnosed mycosis fungoides (MF), a type of cutaneous lymphoma. The study found that the most common first-line therapy was skin-directed therapy (SDT), while a smaller percentage received systemic therapy. The use of systemic therapy was significantly associated with higher clinical stage, presence of plaques, higher severity assessment, and folliculotropic MF. The overall response rate to SDT was higher than that of systemic treatments, and health-related quality of life improved in patients with responsive or stable disease. The researchers concluded that future treatment guidelines for early-stage MF should address these issues. [Extracted from the article]

A 78-year-old man experienced the progression of mycosis fungoides (MF) while being treated with pembrolizumab for renal cell carcinoma (RCC). The man had previously undergone radical nephrectomy for RCC and had received phototherapy for MF. After starting pembrolizumab, he developed swelling and proptosis in the right eye, which was confirmed to be MF. The MF rapidly progressed, with severe swelling and erythema of the eyelid and surrounding skin. A rapidly growing mass was also noted on his left thigh. Despite receiving radiation therapy for the right eye, the man's condition deteriorated rapidly and he passed away after three months. [Extracted from the article]

A 40-year-old woman with blastic plasmacytoid dendritic cell neoplasm underwent treatment with various antineoplastic drugs, including cyclophosphamide, gemcitabine, doxorubicin-liposomal, methotrexate, vincristine, and prednisolone. Despite receiving multiple treatments, her condition did not improve, and a lack of efficacy was observed. The woman experienced pain and swelling in her right cheek, and subsequent biopsies confirmed non-Hodgkin's lymphoma and mycosis fungoides. The patient's lesions aggressively progressed, and additional treatments, including radiotherapy, were administered. However, her condition continued to worsen, leading to the conclusion that the antineoplastic drugs were not effective in treating her condition. [Extracted from the article]

A study conducted at Ryhov County Hospital in Jonkoping, Sweden, examined the prognostic value of histopathological features in early-stage mycosis fungoides (MF), a type of cutaneous lymphoma. The study analyzed histopathological parameters such as lymphocyte infiltrate, Pautrier microabscesses, and lymphocyte atypia in 83 MF patients. The findings suggested that patients with certain histopathological features, such as a high count of lymphocytes and atypical lymphocytes, had worse overall and progression-free survival. The study identified potential prognostic factors that could guide tailored therapeutic approaches for MF patients, but further research is needed to confirm these findings. [Extracted from the article]

2023 MAR 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on mycosis fungoides is the subject of a new report. [...]

A recent study conducted at University Hospital 12 Octubre in Madrid, Spain, explored the use of pegylated interferon A-2a (PEG-IFN-alpha-2a) as a treatment for mycosis fungoides (MF) and Sezary syndrome (SS), which are chronic malignant diseases. The study included 105 patients from 10 countries and found that combination treatment with PEG-IFN-alpha-2a resulted in a longer time to next treatment (TTNT) compared to monotherapy. The overall response rate (ORR) was 53.3%, with a complete response seen in 13% of patients and a partial response in 40%. Adverse events were reported in 68.6% of patients, with flu-like symptoms, lymphopenia, and elevated liver function being the most common. The study concluded that combination regimens and higher doses of PEG-IFN-alpha-2a were associated with a higher ORR. [Extracted from the article]

A 72-year-old woman experienced several adverse reactions during her treatment for mycosis fungoides and Sezary syndrome. She developed neutropenia while taking bexarotene and grade-III lymphopenia and eosinophilic folliculitis while receiving mogamulizumab. The woman's neutropenia persisted despite dose adjustments and discontinuation of bexarotene. She achieved a complete response with mogamulizumab but developed lymphopenia and skin symptoms, which were diagnosed as eosinophilic folliculitis. Treatment with clobetasol helped resolve the folliculitis, but the woman experienced persistent alopecia. She was later diagnosed with hyperthyroidism and liver dysfunction. [Extracted from the article]

A recent study conducted by researchers at Public Assistance - Paris Hospitals (AP-HP) focused on Sezary syndrome, a subtype of cutaneous T-cell lymphoma (CTCL). The study examined the case of a 62-year-old female patient who developed Sezary syndrome while undergoing atezolizumab treatment for tumor-stage transformed mycosis fungoides (MF). Despite various treatments, including oral drugs and radiation therapy, the patient's condition did not improve. The researchers concluded that the emergence of Sezary syndrome during atezolizumab treatment highlights the potential risks and complexities of using PD-L1 inhibitors for CTCL treatment. [Extracted from the article]

A recent study conducted at the University of Pittsburgh has shed light on the cellular origin and differentiation trajectories of cutaneous T-cell lymphomas, specifically mycosis fungoides (MF) and Sézary syndrome (SS). The researchers used TCR sequencing and targeted transcriptomics to analyze single-cell samples from MF and SS patients. The findings revealed distinct populations of CD4+ T cells in SS compared to MF, as well as different subsets of malignant cells within SS. These findings provide valuable insights into the relationship between MF and SS and may contribute to the development of more effective therapeutic strategies. [Extracted from the article]

A recent study conducted at the University of Milan in Italy focused on mycosis fungoides (MF), a type of cutaneous lymphoma. The researchers examined two cases of epidermotropic T-cell lymphoma with an MF-like clinical pattern and ALK expression and molecular alteration. They found that ALK+ primary cutaneous T-cell lymphomas (pcTCL) are rare and can present with a broader range of disease patterns, including those that mimic MF and primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma. The study suggests that targeted therapy may be an option for advanced stages of ALK+ pcTCL, based on ALK expression. However, more research is needed to determine the optimal management approach. [Extracted from the article]

Researchers from Autonomous University in Madrid, Spain have published a report on a distinctive presentation of Mycosis Fungoides (MF), a type of cutaneous lymphoma. The report highlights two cases of MF with clinical urticarial lesions and blood involvement that responded to mogamulizumab treatment. The researchers emphasize the importance of histopathology in diagnosing atypical presentations of MF and note that a low suspicion threshold is necessary for accurate diagnosis. This research has been peer-reviewed and published in the Journal of Cutaneous Pathology. [Extracted from the article]

Researchers at the University of Virginia have discussed new data on mycosis fungoides, the most common type of primary cutaneous T-cell lymphoma. They emphasize the importance of recognizing variants of mycosis fungoides with different immunophenotypes to ensure accurate diagnosis and appropriate management. The researchers present a case of a 49-year-old male with an unusual NK/T-cell phenotype and describe the diagnostic challenges posed by null T-cell phenotype mycosis fungoides with aberrant expression of CD56 and CD20. They conclude that this variant is rare, diagnostically challenging, and can lead to misdiagnosis of aggressive lymphoma subtypes. [Extracted from the article]

Researchers at the Department of Dermatology have described a rare case of mycosis fungoides, a type of cutaneous T-cell lymphoma, initially misdiagnosed as pigmented purpura. The patient, a 44-year-old woman, developed a skin condition on the base of her left thumb. The distinct characteristics of the rash, including discrete patches with colored dots and progressive thickening and pigmentation, prompted further investigation and led to the correct diagnosis. The patient's treatment involved a combination of steroids and narrowband UV therapy. This case highlights the importance of accurately diagnosing uncommon dermatological disorders to ensure appropriate medical intervention. [Extracted from the article]

A new report from researchers at Memorial Sloan-Kettering Cancer Center in New York City highlights racial disparities in mycosis fungoides/Sezary syndrome, a type of cutaneous lymphoma. The study found that black patients had worse survival outcomes compared to white patients, with different survival risks associated with hypopigmentation, erythroderma, and ulceration between the races. The researchers suggest that further investigation is needed to understand the underlying mechanisms and potential impact on treatment strategies. This study provides valuable insights into the differences in clinical presentation and outcomes based on race in patients with mycosis fungoides/Sezary syndrome. [Extracted from the article]

Researchers at Harvard Medical School have conducted a retrospective cohort study to evaluate adherence to guidelines for mycosis fungoides and Sezary syndrome clinical trials. The study found that mean adherence to the guidelines was approximately 60% among the included trials. However, there was no significant difference in adherence between trials that began in the first 6 years after the publication of the guidelines and those that started after. Pivotal trials supporting new therapies were more likely to implement the recommendations. The findings suggest that the guidelines are not consistently implemented across all trials. [Extracted from the article]

A recent study from the University of Florence School of Medicine explores the treatment options for mycosis fungoides, the most common type of cutaneous T-cell lymphoma. The study highlights the multiphasic nature of the disease, with early stages being less aggressive and later stages progressing more rapidly. The researchers discuss the use of skin-directed therapies and biologic response modifiers in the early stages, and radiotherapy and systemic therapies in the later stages. The paper emphasizes the lack of a universally accepted approach to treatment and provides a comprehensive review of the available options. [Extracted from the article]

A recent report from researchers at Galliera Hospital discusses the use of radiation therapy in the treatment of mycosis fungoides, a type of cutaneous lymphoma. The researchers highlight the various techniques and indications for radiation therapy in these patients, emphasizing its effectiveness in improving quality of life and treatment outcomes. They suggest that a multidisciplinary approach and understanding of current methods and mechanisms of action can encourage the use of radiation therapy as a skin-directed therapy. For more information, readers can refer to the article "Radiation therapy in mycosis fungoides" published in Dermatology Reports. [Extracted from the article]

A recent study conducted by researchers at the San Gallicano Dermatological Institute IRCCS focused on mycosis fungoides, the most common primary cutaneous T-cell lymphoma. The disease is characterized by the development of plaques and nodules after an initial non-specific phase. The researchers emphasized the challenges in diagnosing mycosis fungoides early due to its ability to mimic other skin disorders. They recommended multiple biopsies and careful correlation of clinical and pathological findings for a conclusive diagnosis. The study also discussed the various variations of mycosis fungoides and its benign mimics. [Extracted from the article]

A recent study conducted in Ankara, Turkey, investigated the potential role of the C-reactive protein to albumin ratio (CAR) as a diagnostic and prognostic indicator in mycosis fungoides (MF), a type of cutaneous lymphoma. The study analyzed the electronic medical records of 97 MF patients and found that the CAR was significantly higher in MF patients compared to the control group. However, the CAR did not have prognostic significance in terms of disease progression. The researchers suggest that the CAR could be a useful tool in diagnosing MF when faced with difficulties. [Extracted from the article]

A clinical trial, NCT06382844, has been initiated to enhance the detection and measurement of tumor cells in patients with cutaneous T-cell lymphoma (CTCL). The current flow cytometry techniques used in clinical laboratories do not allow for accurate comparison of results in a clinical setting. The project aims to apply standardized strategies of next-generation flow cytometry to detect and quantify tumor cells in CTCL patients. The study will involve developing optimal marker combinations, evaluating the specificity and sensitivity of the new procedure, creating reference databases for automated analysis of cytometry data, and validating the method in multiple centers. Additionally, the project will explore the relationship between the tumor microenvironment and the clinical-biological heterogeneity of the tumor. A new standardized flow cytometry strategy has been developed to detect and measure circulating tumor cells in CTCL patients, with the goal of supporting dermo-hematological diagnosis and improving the accuracy of early diagnosis and treatment response assessment. The study is currently enrolling CTCL patients and is expected to be completed by December 2026. The research is being conducted in Spain through a collaboration between the Instituto de Investigacion Biomedica de Salamanca and the Carlos III Health Institute. [Extracted from the article]

A recent research report from King Saud University and King Saud University Medical City provides new insights into mycosis fungoides, the predominant form of primary cutaneous T-cell lymphoma. The report highlights the rare occurrence of the CD4-/CD8- double-negative variant of mycosis fungoides, which is observed in approximately 12% of early-stage cases and more prevalent in tumor-stage instances. The researchers aim to enhance clarity and comprehension of this variant through a detailed exploration of its spectrum. This information is valuable for individuals conducting research on cancer, dermatology, and lymphoproliferative disorders. [Extracted from the article]

This article presents the interim findings of a study sponsored by Kyowa Kirin, Inc. The study, called "Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sezary Syndrome (PROSPER)," aims to evaluate the impact of mogamulizumab on disease symptoms and quality of life in patients with cutaneous T-cell lymphoma (CTCL). CTCL is a rare form of non-Hodgkin lymphoma that primarily affects the skin and can cause severe itching. The study found that within four weeks of treatment initiation, patients reported improvement in all symptoms, including skin itch, redness, flaking, and pain. The study suggests that mogamulizumab may have a positive impact on patients' symptoms and quality of life. [Extracted from the article]

A French study involving 122 patients with sezary syndrome or mycosis fungoides found that some patients experienced adverse effects during treatment with mogamulizumab. These effects included tumour lysis syndrome, nausea, and thrombopenia. One patient, who was 78 years old, also did not respond well to antihyperuricemic treatment with rasburicase. Despite receiving hydration and rasburicase, this patient developed multiple episodes of tumour lysis syndrome and ultimately died. The study concluded that mogamulizumab may have contributed to these adverse effects. [Extracted from the article]

A man in his 50s developed bullous cutaneous T-cell lymphoma (CTCL) while being treated with dupilumab for adult-onset atopic dermatitis. He presented with pruritus and scaly plaques covering 60% of his body, and further investigation confirmed the diagnosis of adult-onset atopic dermatitis. After receiving two injections of dupilumab, his skin condition worsened and a skin biopsy revealed CTCL. He was treated with photochemotherapy, bexarotene, and valacyclovir, but later developed fever, bullae, and erosions. The diagnosis of toxic epidermal necrolysis (TEN) was considered, but not confirmed histologically. He was subsequently treated with dexamethasone, immunoglobulin, rituximab, and chemotherapy, but his condition deteriorated and he was transferred to hospice care. [Extracted from the article]

A retrospective study involving 79 patients treated for mycosis fungoides (MF) found that one patient experienced a lack of efficacy during treatment with chlormethine gel. The patient, whose age and sex were not provided, showed disease progression after three months of chlormethine treatment. This suggests that chlormethine may not be effective for MF. [Extracted from the article]

A man in his late 60s developed hyperglycemia during treatment with brentuximab-vedotin for mycosis fungoides. Despite receiving insulin treatment, his hyperglycemia persisted, indicating a lack of efficacy. The patient also had a history of well-controlled type 2 diabetes and hepatic cirrhosis. He was given amoxicillin/clavulanic-acid and hydration, as well as methylprednisolone, which corrected the hyperglycemia. However, he later died from upper gastrointestinal bleeding. [Extracted from the article]

A retrospective study conducted in Italy described 14 patients who experienced relapse or new-onset of various cutaneous lymphoproliferative disorders (CLPDs) after receiving COVID-19 vaccinations. Some patients had prior CLPDs, while others did not. The patients received different vaccines, including elasomeran, tozinameran, or AZD-1222. The CLPDs manifested within 3-30 days after vaccination and were treated with various interventions, such as corticosteroids, surgical excision, and radiotherapy. Most patients achieved complete or partial remission. [Extracted from the article]

A man with mycosis fungoides (MF) experienced lack of efficacy with multiple drugs, including cyclophosphamide, doxorubicin, etoposide, methylprednisolone, prednisone, and vincristine. He then developed MF hyperprogression while being treated with nofazinlimab. Despite previous treatments and the use of high-dose methylprednisolone, his disease rapidly progressed and he ultimately passed away. This case highlights the challenges in treating MF and the need for further research in finding effective therapies. [Extracted from the article]

A retrospective study of 122 patients found that an adult patient developed tumour lysis syndrome while being treated with mogamulizumab for sezary syndrome. The patient eventually died due to the syndrome, which was attributed to the use of mogamulizumab. The study does not provide specific details about the patient's age, sex, dosage, route, or duration of treatment. [Extracted from the article]

In a multicenter study involving 54 patients diagnosed with mycosis fungoides (MF), a patient exhibited a lack of efficacy following treatment with chlormethine for MF. The patient, whose age and sex were not stated, was diagnosed with MF stage IIB and enrolled in the study. Despite treatment with chlormethine gel, the patient's disease continued to progress, leading to the discontinuation of chlormethine therapy. [Extracted from the article]

A recent study conducted by researchers at Oxford University Hospitals NHS Foundation Trust in the United Kingdom focused on mycosis fungoides, a type of cutaneous lymphoma, in pediatric patients. The study found that diagnosing these diseases in children can be challenging due to their clinical and pathological heterogeneity. The researchers emphasized the importance of providing age-appropriate patient information and psychological support, as well as the need for further long-term data and guidance on management. The study presented clinical outcomes for a cohort of five pediatric patients with mycosis fungoides and discussed the combined approach of clinical expertise and psychological support in a dermatology pediatric service. [Extracted from the article]

2022 NOV 19 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on mycosis fungoides is the subject of a new report. [...]

4A Corticosteroid-responsive disorders PRESCRIBING NOTES Corticosteroids are potent drugs that affect many organ systems. The doses of these drugs must be individualized. Corti-costeroid-responsive conditions include: Adrenocortical insufficiency: Hydrocortisone, cortisone; prednisone [...]

4A Corticosteroid-responsive disorder PRESCRIBING NOTES Corticosteroids are potent drugs that affect many organ systems. The doses of these drugs must be individualized. Corticosteroid-responsive conditions include: Adrenocortical insufficiency: Hydrocortisone, cortisone; prednisone [...]

4A Corticosteroidresponsive disorders PRESCRIBING NOTES Corticosteroids are potent drugs that affect many organ systems. The doses of these drugs must be individualized. Corticosteroid-responsive conditions include: Adrenocortical insufficiency: Hydrocortisone, cortisone; prednisone [...]